Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress

Strasbourg, France, March 26, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced a 30-minute oral presentation on TG4050, the Company’s Individualized Neoantigen Therapeutic Vaccine (INTV) at the World Vaccine Congress (WVC), taking place from March 31 to April 2, 2026, in Washington, D.C., USA. The presentation will be held on April 1^st.

The presentation will highlight findings of the Phase 1 part of the ongoing Phase 1/2 trial in head and neck cancer. Transgene will also discuss the potential of INTVs to reshape early-stage cancer treatment.

“We are delighted to share our positive data on our lead asset TG4050 with the scientific community”, said Katell Bidet Huang, PhD, Head of Translational Medicine at Transgene.

“TG4050 is a highly innovative, AI-powered, immunotherapy designed individually for each patient, based on its tumor characteristics. In our Phase 1 trial, we were able to show that patients with resected head and neck cancer treated with our vaccine had developed new immune responses targeting preselected neoantigens present in the tumor cells, and TG4050-treated patients were all tumor-free 2 years after the start of their immune treatment. The comprehensive translational data generated to date supports our proposed mechanism of action and the ongoing Phase 2 trial. This technology could be applied across multiple solid tumors where significant unmet medical need remains. With the myvac® platform, Transgene will continue generating clinical data in patients with head and neck cancer and in an additional indication with the aim of preventing cancer relapse for patients at risk.”

About the Oral Presentation:

• Title: TG4050, an Individualized Neoantigen Therapeutic Vaccine in early-stage cancer treatment
• Speaker: Dr Katell Bidet Huang, PhD, Head of Translational Medicine, Transgene
• Session: Cancer & Immunotherapy Vaccines Conference - Early Development/Target selection & discovery
• Date: April 1^st, 2026, at 12:10 PM

Download our Two Pager dedicated to Individualized Neoantigen Therapeutic Vaccines Here (https://www.transgene.com/wp-content/uploads/2026_TwoPager_INTV.pdf)